The Receptor Tyrosine Kinase AXL in Cancer Progression

The AXL receptor tyrosine kinase (AXL) has emerged as a promising therapeutic target for cancer therapy. Recent studies have revealed a central role of AXL signaling in tumor proliferation, survival, stem cell phenotype, metastasis, and resistance to cancer therapy. Moreover, AXL is expressed within...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 8; no. 11; p. 103
Main Authors Rankin, Erinn B, Giaccia, Amato J
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 09.11.2016
MDPI
Subjects
AXL
Cancer
cancer stem cell phenotype
decoy receptor
GAS6
Genotype & phenotype
immune suppression
Immune system
Kinases
Metastasis
proliferation
resistance
Review
small molecule
Stem cells
therapy
small molecule
decoy receptor
proliferation
AXL
metastasis
therapy
cancer stem cell phenotype
GAS6
immune suppression
resistance
Online AccessGet full text

Cover

More Information
Summary:The AXL receptor tyrosine kinase (AXL) has emerged as a promising therapeutic target for cancer therapy. Recent studies have revealed a central role of AXL signaling in tumor proliferation, survival, stem cell phenotype, metastasis, and resistance to cancer therapy. Moreover, AXL is expressed within cellular components of the tumor microenvironment where AXL signaling contributes to the immunosuppressive and protumorigenic phenotypes. A variety of AXL inhibitors have been developed and are efficacious in preclinical studies. These agents offer new opportunities for therapeutic intervention in the prevention and treatment of advanced disease. Here we review the literature that has illuminated the cellular and molecular mechanisms by which AXL signaling promotes tumor progression and we will discuss the therapeutic potential of AXL inhibition for cancer therapy.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers8110103